Geographic atrophy treatment has a new entrant: OliX Pharmaceuticals filed a US IND for OLX301A, a siRNA drug targeting MyD88, the retinal inflammation amplifier Syfovre and Izervay cannot silence.

KOZHIKODE: In an unprecedented display of grassroots solidarity, mountainous Mukkam, in Kozhikode, has transformed into a ...

Patients with geographic atrophy prefer treatments that preserve reading ability and distance vision despite potential risks of inflammation.

Teva Pharmaceutical Industries is discontinuing a Phase 2 study for a multiple system atrophy treatment. The company said Monday the move follows a recommendation from an independent data monitoring ...

A prospective neuroimaging study finds that atrophy patterns across frontotemporal dementia syndromes spatially align with ...

A cross-sectional study of 94 patients links visually assessed putaminal MRI markers to contralateral parkinsonian motor severity in multiple system atrophy, while infratentorial signs track ...

Israeli drugmaker Teva Industries said it will discontinue its Phase II TOPAS-MSA study of emrusolmin (TEV-‘286) in adults with multiple system atrophy (MSA), after an interim analysis indicated a ...

Teva ends its Phase II TOPAS-MSA emrusolmin trial in multiple system atrophy after a futility analysis. Read now to see what it means for MSA patients.

(Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today ...

Emrusolmin is being developed in partnership with MODAG GmbH. Teva said the decision concerns TOPAS-MSA and does not represent a final decision on the broader emrusolmin program. In pre-market trading ...

In this video, Jennifer I. Lim, MD, discusses phase 2 data on OCU410 presented at the American Academy of Ophthalmology meeting.

The Department of Health's adoption of affordable generic Risdiplam for Spinal Muscular Atrophy marks a major victory for ...